{"id":24608,"date":"2022-11-07T01:39:00","date_gmt":"2022-11-06T17:39:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24608"},"modified":"2025-02-01T01:48:29","modified_gmt":"2025-01-31T17:48:29","slug":"organons-q3-results-show-womens-health-segment-outperforms-amid-global-revenue-decline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24608","title":{"rendered":"Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline"},"content":{"rendered":"\n

US-based Organon & Co. (NYSE: OGN<\/a>), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK<\/a>) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up 3% if excluding the impact of currency exchange fluctuations (ex-FX).<\/p>\n\n\n\n

Global Segment Performance<\/strong>
Globally, key performers included the Women’s Health segment, which reported a 19% increase in revenues and a 23% increase ex-FX over the three months. Nexplanon (etonogestrel implant) was highlighted as a significant growth driver. Fertility drugs also saw continued demand, with Follistim AQ (follitropin beta injection) increasing by 2% ex-FX and ganirelix acetate injection rising by 52% ex-FX. Biosimilars were down 4% ex-FX, while Established Brands decreased by 2% ex-FX.<\/p>\n\n\n\n

China Market Performance<\/strong>
China remains a key market for Organon, driven by the over 1 million IVF cycles conducted annually, a volume five times that of the United States. China sales reached USD 241 million, down 4% YOY in actual terms but up 1% YOY ex-FX.<\/p>\n\n\n\n

CEO Commentary and Future Outlook<\/strong>
Speaking during the earnings conference call, CEO Kevin Ali highlighted the reacquisition from Bayer AG of rights to oral contraceptive brands Marvelon and Mercilon in certain Asian territories, including China and Vietnam, a deal struck in February this year. Ali noted, \u201cSince we have taken ownership of Marvelon, growth has outpaced the market and we increased market share of the product by two points in China.\u201d<\/p>\n\n\n\n

Organon has also benefited from the delay in the implementation of round seven of the national volume-based procurement (VBP) program, which included its cardiovascular drug Ezetrol. Ali noted during the conference call that the VBP program is set to have a significant impact on China sales, with \u201cmore than three-quarters of our business\u201d expected to go through VBP by the end of 2023. Offsetting the impact of VBP is the fact that \u201calmost 50% of our business is going through the retail channel, and more and more of that business is now starting to go through the e-commerce channel.\u201d Ali acknowledged that \u201cthe protracted nature of lockdowns in China\u201d has led to \u201cslower than anticipated recovery, particularly in the fertility clinics and the overall retail market.\u201d However, Organon still views China as set to return to a high single-digit growth trajectory either in 2023 or 2024: \u201cWe still feel very good about our business in China and in our ability to grow our business in China,\u201d said Ali.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[88,20,27,2675,176,903,972,174,78],"class_list":["post-24608","post","type-post","status-publish","format-standard","hentry","category-company","tag-e-commerce","tag-finance","tag-finanical-reports","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-nyse-ogn","tag-organon","tag-otc-retail"],"yoast_head":"\nOrganon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women\u2019s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up 3% if excluding the impact of currency exchange fluctuations (ex-FX).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24608\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Organon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24608\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-06T17:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T17:48:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline\",\"datePublished\":\"2022-11-06T17:39:00+00:00\",\"dateModified\":\"2025-01-31T17:48:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"E-commerce\",\"Finance\",\"Finanical Reports\",\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\",\"NYSE: OGN\",\"Organon\",\"OTC \\\/ retail\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24608#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24608\",\"name\":\"Organon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-06T17:39:00+00:00\",\"dateModified\":\"2025-01-31T17:48:29+00:00\",\"description\":\"US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women\u2019s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up 3% if excluding the impact of currency exchange fluctuations (ex-FX).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24608\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24608#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Organon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline - Insight, China's Pharmaceutical Industry","description":"US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women\u2019s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up 3% if excluding the impact of currency exchange fluctuations (ex-FX).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24608","og_locale":"en_US","og_type":"article","og_title":"Organon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24608","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-06T17:39:00+00:00","article_modified_time":"2025-01-31T17:48:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24608#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24608"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline","datePublished":"2022-11-06T17:39:00+00:00","dateModified":"2025-01-31T17:48:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24608"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["E-commerce","Finance","Finanical Reports","Merck Sharp & Dohme","MSD","NYSE: MRK","NYSE: OGN","Organon","OTC \/ retail"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24608#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24608","url":"https:\/\/flcube.com\/?p=24608","name":"Organon's Q3 Results Show Women's Health Segment Outperforms Amid Global Revenue Decline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-06T17:39:00+00:00","dateModified":"2025-01-31T17:48:29+00:00","description":"US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women\u2019s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up 3% if excluding the impact of currency exchange fluctuations (ex-FX).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24608#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24608"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24608#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24608"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24608\/revisions"}],"predecessor-version":[{"id":24609,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24608\/revisions\/24609"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}